Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011860 (type 2 diabetes)
 57,723 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The self-monitoring of blood glucose (SMBG), traditionally performed by "point-of-care" (POC) devices called portable glucose monitors (PGM) is now considered an integral part of managed care of diabetic patients, especially type 1 diabetics and those on insulin therapy. In patients with type 2 diabetes, SMBG can help to achieve a better glycaemic control, although there is not sufficient evidence to attest that strict monitoring in these patients is associated with an improved outcome. The outcome of several clinical studies, especially in diabetics on insulin therapy, has shown that SMBG plays a key role in preventing complications in the short, medium and long term. According to the current recommendations, SMBG is aimed to achieve and maintain glycaemic control, prevent and identify hypoglycaemia, prevent severe hyperglycaemia, adjust lifestyle changes and establish the need to begin treatment with insulin in gestational diabetes mellitus. However, as clearly highlighted by the American Diabetes Association (ADA) and the National Academy of Clinical Biochemistry (NACB), patients and healthcare personnel should be trained on the appropriate use of the device, as well as on the correct interpretation of data. Moreover, definite analytical targets and appropriate acceptance criteria for performance should be fulfilled before a new device is introduced in the hospital environment, or recommended to the patients. Performance limitations such as hematocrit extremes and analytical interferences should be clearly acknowledged by the operators, before taking test results for granted. The current article aims to review the current indications for SMGB and highlight the most important criteria for the appropriate use of PGMs.
 ...
PMID:Overview on self-monitoring of blood glucose. 1916 74

The utility of self-monitoring of blood glucose (SMBG) in patients with type 1 diabetes and in those with type 2 diabetes treated with insulin is well accepted, however, consensus on whether people with type 2 diabetes who are not taking insulin should monitor their blood glucose levels has not been reached. The aim of the present review was to analyze data available on SMGB in type 2 diabetic patients and subsequently elaborate recommendations for its use. Nine clinical trials and 5 systematic reviews were consulted. Furthermore, guides from scientific societies were also consulted. I can conclude, under my personal point of view that SMBG must be introducing as part of a structured education programme for those newly diagnosed with type 2 diabetes even in those only treated with life-style modifications provides people with the opportunity to learn about the impact that food and physical activity have on their glycaemia control. These patients should monitor their blood glucose pre- and post-prandial at least once per month. The frequency should increase when values of glycosilate haemoglobin are out of the objectives.
 ...
PMID:[Self-monitoring of blood glucose in type 2 diabetic patients non treated with insulin]. 2011 74